

Jublia (efinaconazole)

Effective Date: 8/18/2020

Date Developed: 8/18/2020 by Dr. H. Taekman

Last Approval Date: 8/18/2020, 2/2/21, 8/3/21, 2/1/22,
1/31/23

Jublia is indicated for the treatment of onychomycosis due to *Trichophyton rubrum* and *Trichophyton mentagrophytes*. Presence of these organisms may be determined using molecular diagnostic testing. Fungal cultures require a longer turnaround time to obtain diagnosis.

Pre-Authorization Criteria:

Jublia will be approved based on all of the following criteria:

1. Submission of medical records (laboratory and clinical documentation) confirming diagnosis of onychomycosis of the toenail with of one of the following infections (if request is for a subsequent course of therapy a new test must be performed):

- a. *Trichophyton rubrum*
- b. *Trichophyton mentagrophytes*

-AND-

2. Treatment is requested due to medical condition and not for cosmetic purposes (e.g. patients with history of cellulitis of the lower extremity who have ipsilateral toenail onychomycosis, patients with diabetes who have additional risk factors for cellulitis, patients who experience pain/discomfort associated with the infected nail)

-AND-

3. History of failure (subject to minimum treatment durations indicated below), contraindication, or intolerance to **two** of the following antifungal agents (please document date of trial):

- a. Minimum of 12 week treatment with itraconazole (generic Sporanox)
- b. Minimum of 12 week treatment with oral terbinafine (generic Lamisil)
- c. Minimum of 12 week treatment with ciclopirox (generic Penlac)

References:

1. *Jublia (efinaconazole) [prescribing information]. Bridgewater, NJ: Bausch Health US, LLC; July 2020.*

Lipner SR, Scher RK. Efinaconazole in the treatment of onychomycosis. Infect Drug Resist. 2015;8:163-172. [PubMed [26082652](#)]

Revision History:

Date Developed: 7/21/2020 by Howard Taekman, MD

Date Approved by P&T Committee: August 18, 2020

Date Reviewed/No Updates: 2/2/21 by H. Taekman, MD; R. Sterling, MD

Date Approved by P&T Committee: 2/2/21

Date Reviewed/ Updated: 8/3/21 by H. Taekman, MD; R. Sterling, MD

Date Approved by P&T Committee: 8/3/21

Date Reviewed/No Updates: 2/1/22 by H. Taekman, MD; R. Sterling, MD

Date Approved by P&T Committee: 2/1/22

Date Reviewed/No Updates: 1/31/23 by H. Taekman, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/31/23

Revision Date	Content Revised (Yes/No)	Contributors	Review/Revision Notes
8/18/20	New	Howard Taekman, MD	New
2/2/21	No	Howard Taekman, MD; Robert Sterling, MD	Annual review
8/3/21	Yes	Howard Taekman, MD; Robert Sterling, MD	Added References
2/1/22	No	Howard Taekman, MD; Robert Sterling, MD	Annual review
1/31/23	No	Howard Taekman, MD; Robert Sterling, MD	Annual review